RePORT International Resources

The SAMRC’s vision is to build a healthy nation through research and innovation. For this vision to be realised, health researchers (locally and internationally) need funding to access the necessary resources and facilities. While the SAMRC funds many internal and external research projects itself, as well as in collaboration with partnering institutions, it also connects innovative researchers with like-minded organisations across the world that provide funding opportunities.

The Southeastern National Tuberculosis Center (SNTC) offers education, training, research support, and program development resources for healthcare professionals and public health providers. Please explore the website for more details.

Video in multiple languages for collecting sputum sample

This questionnaire was designed for symptom measurement for persons with COPD and asthma. However, it is commonly used for persons with pulmonary TB in both clincal and reseatch settings.

Watch webinars, event recordings, and advocacy videos from the Stop TB Partnership.

A session from the 78th World Health Assembly focused on new financing models and emerging technologies in TB. Speakers emphasized sustainable investment and digital health tools to improve prevention, diagnosis, and treatment.

This session called for increased domestic TB funding in Africa, private sector engagement, and innovation in service delivery, governance, and regulation—underscoring community-driven and politically aligned strategies.

Several training packages.

This three-part webinar series by the Stop TB Partnership and FIND provides an in-depth overview of targeted next-generation sequencing (tNGS) technology for detecting drug-resistant tuberculosis. The series covers fundamental principles of tNGS, its advantages over traditional diagnostic methods, and practical guidance on implementing tNGS in high-burden and resource-limited settings. Featuring expert insights and case studies, the webinars highlight early program experiences and discuss how tNGS supports WHO-endorsed strategies to improve rapid and comprehensive detection of TB drug resistance worldwide.

This website features TAG’s latest updates in the fight to end HIV/AIDS, Hepatitis C, and Tuberculosis. It includes the Pipeline Report on innovations in diagnosing, preventing, treating, and curing HIV, HCV, and TB; information on TB research funding; recorded webinars; advocacy letters and comments submitted or endorsed by TAG; and official press releases and statements.

Please refer to the link for the TAG's latest edition of TB Treatment Pipeline Report. The report provides the latest information on 22 new or repurposed drugs in clinical development for TB and summarizes ongoing, planned, and recently completed trials. Included in this year's report are: Results from the phase 3 endTB-Q trial and two phase 2b/c trials of quabodepistat-containing regimens completed or discontinued in 2024; First-of-their-kind trials focused on asymptomatic TB and bedaquiline-resistant TB; The first long-acting formulation of a TB drug to enter clinical development; and The first phase 3 trial of a new drug from a new class since bedaquiline and delamanid.

The new 2025 update of An Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis lays out what community advocates need to know about WHO-recommended regimens for drug-resistant TB. The Activist Guide reviews the evidence-base behind these regimens, important considerations for key populations affected by TB, the access landscape, and more. The publication is intended to equip advocates with information they need to formulate arguments and push for universal implementation of the best available treatments.

TAG’s Cheat Sheets for Tuberculosis Activists are designed to help advocates navigate the range of tools in use and in the research pipeline.

To accompany the updated Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis, TAG also developed three additional educational materials to support community-based and civil society organizations leading treatment literacy, peer support, and community-led monitoring activities:

The World Health Organization (WHO) guidelines for diagnosing TB have evolved along with available technologies and tools that are increasingly accurate, simple, and efficient at detecting TB and resistance to a wider range of TB drugs. Despite this progress, 2.7 million individuals with TB still remain undiagnosed and undetected. On July 17th, 2025, TAG hosted a community webinar on tests for TB and drug resistance. The webinar breaks down the latest WHO guidelines and explores the most effective tools for diagnosing TB and drug resistance. The webinar also launched TAG’s updated resource, An Activist’s Guide to Diagnostic Tools for Tuberculosis, and provides a deep dive into two sections of the Guide: (1) the array of WHO-recommended diagnostic tools and how they should be optimally used in country programs; and (2) key access considerations and actions activists can take to ensure that all people at risk of TB receive quality TB diagnostic testing.

From Forest to Factory: Tracing the Supply Chains for Two Modern Adjuvants of Global Health Importance — QS-21 and MPL provides a first-of-its-kind analysis of the global supply chains of two key adjuvants used in several of the world’s most important vaccines. QS-21 and MPL are part of licensed vaccines against malaria, shingles, and respiratory syncytial virus, and in a promising candidate vaccine for tuberculosis (TB) called M72/AS01E.

What Could Go Right: Vital Partnerships with Communities and Civil Society for New Tuberculosis Vaccines, written together with community partners and supported by Wellcome, explores the indispensable role of communities and civil society in preparing the way for new TB vaccines and ensuring their success once they become available.

The Tuberculosis Data, Impact Assessment and Communications Hub (TB DIAH) supports decision-makers by generating, analyzing, and utilizing quality data to inform and scale up effective TB services. This website provides resources on TB M&E and surveillance processes.

A report has been published based on findings of the study conducted in Ukraine: “Studying the Aspects of Gender, Equity, and Inclusion in the Workplace Among Healthcare Professionals Involved in TB Response" https://tbcoalition.eu/resource/files/2025/09/report-on-gender-assessment-among-healthcare-workers-in-ukraine_eng.pdf The aim of the study was to assess the level of implementation of gender equality principles among healthcare workers providing TB diagnostic and treatment services, and to examine the barriers preventing women and men from exercising their right to gender equality. The study employed a triangulation method, which ensured the validity and reliability of the results. As part of this approach, the following methods were used: Desk review, In-depth interviews, Focus group discussions.

National Association of Tuberculosis Patients of the Republic of Moldova “SMIT” published a report with the results of the study ‚ Multidimensional Analysis of Tuberculosis-Related Stigma in the Republic of Moldova. The study was conducted at the request of the National TB Response Program, with the support of the Center for Health Policies and Studies and the TB Europe Coalition, and funded by the Global Fund to Fight AIDS, Tuberculosis and Malaria and the Stop TB Partnership. The assessment was conducted in 2025 and provides a structured analysis of the barriers to accessing human rights-based, gender-sensitive, and population-specific TB care.